Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at the time of screening~* Documented diagnosis of HAE (Type I or II)~* Experiencing ≥2 HAE attacks per year, with at least 1 attack in the past 6 months reported by the participant~* Willing and able to read, understand, and sign an informed consent form~* Females of childbearing potential must agree to be abstinent or else use acceptable forms of contraception throughout study~* Males with female partners of childbearing potential must agree to be abstinent or use a medically acceptable form of contraception throughout study~Exclusion Criteria:~* Exposure to an investigational drug or device within 90 days prior to study~* History of exposure within the past 5 years to a monoclonal antibody or recombinant protein bearing an Fc domain~* Concomitant diagnosis of another form of chronic angioedema~* Use of long-term prophylaxis for HAE within 90 days prior to study~* Use of C1-INH that exceeds a total of 30 days within the past 90 days prior to study; any use of C1-INH within 7 days prior to study~* Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption within 90 days prior to study~* Exposure to androgens within 90 days prior to study~* Presence of an indwelling catheter~* Diagnosis of HIV~* Active liver disease or liver function test abnormalities~* History of substance abuse or dependence~* Pregnancy or breastfeeding~* Any condition that, in the opinion of the Investigator, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DX-2930, Cohort 1 (Type: EXPERIMENTAL): Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
- DX-2930, Cohort 2 (Type: EXPERIMENTAL): Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
- DX-2930, Cohort 3 (Type: EXPERIMENTAL): Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
- DX-2930, Cohort 4 (Type: EXPERIMENTAL): Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).